News
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Immunic, Inc. highlights its 2024 accomplishments and upcoming milestones, including positive trial results for vidofludimus calcium in multiple sclerosis. Strengthened team and secured private placement for future growth -
-
-
COMMUNIQUÉ DE PRESSE
Immunic, Inc. to Participate in Investor Conference in December
Immunic, Inc. to Participate in Investor Conference in December. Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing therapies for chronic inflammatory and autoimmune diseases, announces participation in Piper Sandler 36th Annual Healthcare Conference in New York -
-
-
COMMUNIQUÉ DE PRESSE
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
Immunic announces publication of phase 1/1b clinical trial data of IMU-856 in The Lancet Gastroenterology & Hepatology. Positive results in celiac disease patients. Potential new approach for gastrointestinal diseases -
